Author details

Full Name

Joel M Kremer

Affiliation

ORCID

Career Start Year

1981

Papers

351

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37060528	Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.		2023
36250408	Reply.	Arthritis Care and Research	2023
35953263	Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.	Ann Rheum Dis	2023
37906399	Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study.		2023
37644656	Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis?		2023
37858006	A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis.		2023
37252826	Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics.		2023
35143117	Obesity and Response to Advanced Therapies in Rheumatoid Arthritis.	Arthritis Care and Research	2022
35449236	Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey.	Rheumatology International	2022
36544236	The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry.		2022
33177102	Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US reg	Annals of the Rheumatic Diseases	2022
33002323	Weight Fluctuation and the Risk of Cardiovascular Events in Patients With Rheumatoid Arthritis.	Arthritis Care and Research	2022
34741435	TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study.	ACR Open Rheumatology	2022
34654733	Dr. Kremer et al reply.	Journal of Rheumatology	2022
32719038	Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.	Annals of the Rheumatic Diseases	2021
32374918	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.	Arthritis Care and Research	2021
33630272	Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry.	Rheumatology and Therapy	2021
34215644	Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.	Annals of the Rheumatic Diseases	2021
34157578	Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial.	Seminars in Arthritis and Rheumatism	2021
34047953	Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.	Rheumatology and Therapy	2021
33570260	Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.	ACR Open Rheumatology	2021
34148193	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-Î± Inhibitors: The NETWORK-004 Prospective Observational Study.	Rheumatology and Therapy	2021
34101387	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.	Arthritis Care Res (Hoboken)	2021
34101376	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.	Arthritis Rheumatol	2021
33722953	Methotrexate and Cardiovascular Disease in Patients With Rheumatoid Arthritis: Insights and Novel Speculations.	Journal of Rheumatology	2021
33258003	Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study.	Rheumatology International	2021
33360371	Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.	International Immunopharmacology	2021
33323534	The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies.	Journal of Rheumatology	2021
33158881	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.	Annals of the Rheumatic Diseases	2021
31154414	Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.	Journal of Rheumatology	2020
32314877	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-Inflammatory Drug Users: Real-World Application.	ACR Open Rheumatology	2020
32314534	Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis.	ACR Open Rheumatology	2020
32130579	Prevalence of SjÃ¶gren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry.	Clinical Rheumatology	2020
31637609	Assessing disease severity in bio-naÃ¯ve patients with RA on treatment with csDMARDs: insights from the Corrona Registry.	Clinical Rheumatology	2020
31941801	Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis Is Unaffected by Comorbidity Burden or Obesity: Data from a US Registry.	Journal of Rheumatology	2020
32232740	Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry.	Rheumatology and Therapy	2020
32103630	Physician Prescribing Patterns and Risk of Future Long-Term Opioid Use Among Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study.	Arthritis and Rheumatology	2020
31612736	Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis.	Current Medical Research and Opinion	2020
32449040	Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and SjÃ¶gren's syndrome enrolled in a large observational US registry.	Rheumatology International	2020
31858963	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.	Clinical and Experimental Rheumatology	2020
32759265	Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.	Annals of the Rheumatic Diseases	2020
33028675	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib.	RMD Open	2020
32797404	Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis.	Rheumatology and Therapy	2020
33161375	Hydroxychloroquine and the risk of respiratory infections among RA patients.	RMD Open	2020
32720443	Methotrexate Pulmonary Toxicity: Deep Inspiration.	Arthritis and Rheumatology	2020
31240499	Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.	Rheumatology and Therapy	2019
31647025	Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.	Arthritis Res Ther	2019
31707603	Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis.	Rheumatology and Therapy	2019
30474933	Chronic Opioid Use in Rheumatoid Arthritis: Prevalence and Predictors.	Arthritis and Rheumatology	2019
30647182	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.	Journal of Rheumatology	2019